Advertisement
Advertisement

BDTX

BDTX logo

Black Diamond Therapeutics, Inc. Common Stock

2.48
USD
Sponsored
-0.15
-5.51%
Jan 30, 15:57 UTC -5
Closed
exchange

After-Market

2.48

0.00
0.00%

BDTX Earnings Reports

Positive Surprise Ratio

BDTX beat 20 of 24 last estimates.

83%

Next Report

Date of Next Report
Mar 04, 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.19
Implied change from Q3 25 (Revenue/ EPS)
--
/
+26.67%
Implied change from Q4 24 (Revenue/ EPS)
--
/
-32.14%

Black Diamond Therapeutics, Inc. Common Stock earnings per share and revenue

On Nov 06, 2025, BDTX reported earnings of -0.15 USD per share (EPS) for Q3 25, beating the estimate of -0.23 USD, resulting in a 37.32% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +2.84% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 11 analysts forecast an EPS of -0.19 USD, with revenue projected to reach -- USD, implying an increase of 26.67% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
logo
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
FAQ
For Q3 2025, Black Diamond Therapeutics, Inc. Common Stock reported EPS of -$0.15, beating estimates by 37.32%, and revenue of $0.00, 0% as expectations.
The stock price moved up 2.84%, changed from $3.87 before the earnings release to $3.98 the day after.
The next earning report is scheduled for Mar 04, 2026.
Based on 11 analysts, Black Diamond Therapeutics, Inc. Common Stock is expected to report EPS of -$0.19 and revenue of -- for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement